SCHEMBL654703

SCHEMBL654703

O=C1NC2(CCNCC2)c2ccccc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNKS O95271 1/20 0.44
TNKS2 Q9H2K2 1/20 0.44
HRH3 Q9Y5N1 1/20 0.43
NPY5R Q15761 1/20 0.42
PDE7A Q13946 1/20 0.40
ALDH1A1 P00352 3/20 0.39
POLB P06746 1/20 0.39
BACE1 P56817 1/20 0.39
KDM4E B2RXH2 1/20 0.39
HSD17B10 Q99714 1/20 0.39
GSK3B P49841 1/20 0.39
CASP3 P42574 1/20 0.38
CASP2 P42575 1/20 0.38
CASP7 P55210 1/20 0.38
CASP6 P55212 1/20 0.38
CASP8 Q14790 1/20 0.38
OPRM1 P35372 2/20 0.38
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37
ITGA4 P13612 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6819759 0.98 TNKS (0.43) TNKSTNKS2HRH3NPY5RPDE7A
SCHEMBL29695445 0.89 TNKS (0.48) TNKSTNKS2HRH3NPY5RPDE7A
SCHEMBL15914816 0.89 TNKS (0.48) TNKSTNKS2HRH3NPY5RPDE7A
SCHEMBL11637692 0.85 PDE7A (0.54) TNKSTNKS2HRH3NPY5RPDE7A
SCHEMBL11641417 0.84 PDE7A (0.57) TNKSTNKS2HRH3NPY5RPDE7A
SCHEMBL30930016 0.84 PDE7A (0.57) TNKSTNKS2HRH3NPY5RPDE7A
SCHEMBL6266095 0.82 TNKS (0.47) TNKSTNKS2HRH3NPY5RPDE7A
Boric Acid SCHEMBL29246364 0.82 HRH3 (0.46) TNKSTNKS2HRH3NPY5RPDE7A
SCHEMBL16546757 0.79 TNKS (0.45) TNKSTNKS2HRH3NPY5RPDE7A
SCHEMBL1222680 0.79 KDM4E (0.41) PDE7AALDH1A1BACE1KDM4EOPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220017518-A1 Histone Deacetylase Inhibitors and Methods of Use Thereof REACTION BIOLOGY CORP. 2022-01-20 US disclosed
US-11155550-B2 Histone deacetylase inhibitors and methods of use thereof Reaction Biology Corporation (US) 2021-10-26 US disclosed
US-20200352931-A1 OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE Phenex Discovery Verwaltungs-GmbH (DE) 2020-11-12 US disclosed
US-10407428-B2 Spiro-isoquinoline-1,4′-piperidine compounds having multimodal activity against pain ESTEVE PHARMACEUTICALS, S.A. (ES) 2019-09-10 US disclosed
US-20190270744-A1 Histone Deacetylase Inhibitors and Methods of Use Thereof GOLUB CAPITAL LLC, AS COLLATERAL AGENT 2019-09-05 US disclosed
EP-3221314-B1 SPIRO-ISOQUINOLINE-1,4'-PIPERIDINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN ESTEVE PHARMACEUTICALS SA (ES) 2019-07-03 EP disclosed
WO-2019115586-A1 OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE Phenex Discovery Verwaltungs-GmbH (DE) 2019-06-20 WO disclosed
US-20180111935-A1 SPIRO-ISOQUINOLINE-1,4'-PIPERIDINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN ESTEVE PHARMACEUTICALS, S.A. (ES) 2018-04-26 US disclosed
EP-3221314-A1 SPIRO-ISOQUINOLINE-1,4'-PIPERIDINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN Laboratorios Del. Dr. Esteve, S.A. (ES) 2017-09-27 EP disclosed
EP-2023924-B1 ARYL-FUSED SPIROCYCLIC COMPOUNDS MERCK SHARP & DOHME (US) 2016-08-03 EP disclosed
EP-1817036-A2 MODULATORS OF MUSCARINIC RECEPTORS Vertex Pharmaceuticals Incorporated (US) 2007-08-15 EP disclosed
EP-1795527-A1 CARBAMOYL-SUBSTITUTED SPIRO DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-06-13 EP disclosed
US-20070027173-A1 Indol-3-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists F. HOFFMANN-LA ROCHE AG (CH) 2007-02-01 US disclosed
US-20070027173-A1 Indol-3-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists F. HOFFMANN-LA ROCHE AG (CH) 2007-02-01 US disclosed
US-20070027173-A1 Indol-3-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists F. HOFFMANN-LA ROCHE AG (CH) 2007-02-01 US disclosed
WO-2007006688-A1 INDOL-3-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2007-01-18 WO disclosed
WO-2007006688-A1 INDOL-3-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2007-01-18 WO disclosed
US-20060270653-A1 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED 2006-11-30 US disclosed
WO-2006123242-A1 1, 2, 4 -TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS PFIZER LIMITED (GB) 2006-11-23 WO disclosed
WO-2006058303-A2 MODULATORS OF MUSCARINIC RECEPTORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2006-06-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200352931-A1 OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE IDO1, IDO2, INMT TNKS 1347/4885TNKS2 1516/4885HRH3 658/4885
US-20070027173-A1 Indol-3-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists AVPR1A, AVPR2, AVPR1B TNKS 3425/4885TNKS2 4063/4885HRH3 729/4885
US-20220017518-A1 Histone Deacetylase Inhibitors and Methods of Use Thereof HDAC5, HDAC1, HDAC2 TNKS 412/4885TNKS2 435/4885HRH3 391/4885
US-20060270653-A1 Modulators of muscarinic receptors CHRM3, CHRM5, CHRM2 TNKS 3565/4885TNKS2 3651/4885HRH3 143/4885
US-10407428-B2 Spiro-isoquinoline-1,4′-piperidine compounds having multimodal activity against pain OPRD1, OPRK1, OPRL1 TNKS 1576/4885TNKS2 2486/4885HRH3 1418/4885
US-20180111935-A1 SPIRO-ISOQUINOLINE-1,4'-PIPERIDINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN OPRD1, OPRK1, OPRL1 TNKS 1580/4885TNKS2 2477/4885HRH3 1409/4885
US-11155550-B2 Histone deacetylase inhibitors and methods of use thereof HDAC5, HDAC1, HDAC2 TNKS 412/4885TNKS2 435/4885HRH3 391/4885
US-20190270744-A1 Histone Deacetylase Inhibitors and Methods of Use Thereof HDAC5, HDAC1, HDAC2 TNKS 412/4885TNKS2 435/4885HRH3 391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.